Pharmaceuticals

Outlook for HERG Screening Market: Key Developments and Future Strategies to 2029

September 1, 2025 by Marketing Posting

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Is the Estimated Industry Valuation for the HERG Screening Sector?#_x000D_

The market size for pediatric drugs has seen brisk growth in the past few years, expanding from $157 billion in 2024, it is projected to reach $179.43 billion in 2025, with a compound annual growth rate (CAGR) of 14.3%. The substantial growth during the historical period was fueled by a need for corresponding medicines, a surge in the pediatric population, enhanced understanding of pediatric diseases, the extension of pediatric oncology, the advent of digital health and telemedicine, and escalated partnerships in the development of pediatric drugs._x000D_

_x000D_

Anticipations point towards a swift expansion for the pediatric drugs market in the coming years. It’s projected to escalate to “$308.57 billion in 2029 with a compound annual growth rate (CAGR) of 14.5%. This surge in the future timeline can be credited to factors such as a growing pediatric demographic, the increasing incidence of mental health concerns in children, the swell in chronic conditions amongst children, an elevated rate of vaccinations in minors, and a surge in the demand for pediatric mental health drugs. The forthcoming period will see trends like bespoke pediatric medicine, the inclusion of technology in pediatric drug distribution, telemedicine and digital healthcare solutions, improvement in pediatric clinical trials, and cooperative efforts between pediatricians and pharmacists._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21249&type=smp_x000D_

_x000D_

#What Forces Are Driving The Growth Of The HERG Screening Market?#_x000D_

The increase in heart disorder patients is set to push forward the expansion of the HERG screening market. Heart disorders, also recognized as cardiovascular diseases, are a variety of conditions that can harm the heart and blood vessels, compromising the heart’s capacity to function correctly and potentially leading to severe health issues. Factors such as unhealthy lifestyles, an aging population, genetic predisposition, diabetes, and metabolic syndrome can give rise to these disorders. HERG screening enables the discovery of potential drug prospects, prevention of cardiac incidents that could cause fatal cardiac arrhythmias, especially torsade de pointes (TdP), and enhancement of patient results. For example, a May 2023 report by the US-based Centers for Disease Control and Prevention revealed that 1 in 20 adults aged 20 and above were afflicted with cardiovascular diseases, with 695,000 persons living with these diseases and 375,476 persons dying from them. Moreover, a report from the UK-based Office for National Statistics published in March 2022 stated that 20,061 individuals died from heart attacks, indicating an increase from the previous year. As such, the surge in heart disorder patients is contributing to the escalation of the HERG screening market._x000D_

_x000D_

The pediatric drugs market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs_x000D_

2) By Route Of Administration: Oral, Topical, Parenteral, Other Route Of Administrations_x000D_

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels_x000D_

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Respiratory Disorder Drugs: Asthma Medications, Cystic Fibrosis Treatments, Bronchodilators, Corticosteroids _x000D_

2) By Autoimmune Disorder Drugs: Immunosuppressants, Biologic Therapies, Disease-Modifying Antirheumatic Drugs (DMARDs) _x000D_

3) By Gastrointestinal Drugs: Proton Pump Inhibitors (PPIs), Antiemetics, Antidiarrheals, Laxatives _x000D_

4) By Cardiovascular Drugs: Antihypertensive Medications, Heart Failure Treatments, Antiarrhythmic Drugs, Lipid-lowering Agents_x000D_

_x000D_

#What Notable Trends Are Shaping The Direction Of The HERG Screening Market?#_x000D_

Leaders in the pediatric drugs market, such as Johnson and Johnson, are prioritizing the development of groundbreaking drugs like entirely human monoclonal antibodies for enhanced treatments and reduced side effects in young patients. These antibodies, wholly drawn from human genetics, lower the risk of immune system reactions compared to part human monoclonal antibodies, being produced through sophisticated biotechnology techniques like transgenic mice with human antibody genes or phage display technology. In August 2022, FDA approval for STELARA (ustekinumab), a treatment for pediatric patients who are six years or older suffering from active psoriatic arthritis (PsA) was achieved by Johnson and Johnson. This marked a significant milestone as STELARA is the inaugural biologic therapy that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), central cytokines in inflammatory responses linked with autoimmune diseases. Active PsA is a rare condition in children with chronic inflammatory arthritis, affecting approximately 5-8% of them and causing symptoms like joint swelling and skin lesions._x000D_

_x000D_

#Which Companies Currently Dominate The Competitive Landscape In The HERG Screening Industry?#_x000D_

Major companies operating in the pediatric drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca Plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Co., Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Vertex Pharmaceuticals, UCB Pharma, Sun Pharmaceutical Industries Ltd., Perrigo Company, Shionogi & Co. Ltd., Mallinckrodt, Torrent Pharmaceuticals Ltd, Sarepta Therapeutics, Zydus Cadila _x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/pediatric-drugs-global-market-report_x000D_

_x000D_

#Which Geographic Regions Are Driving Demand In The HERG Screening Market?#_x000D_

North America was the largest region in the pediatric drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pediatric drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21249&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_